Financial Performance - The Group's revenue for the year ended December 31, 2024, was approximately HK$897.5 million, representing an increase of approximately 10.9% compared to HK$809.1 million in 2023[21]. - The Group reported a loss of approximately HK$99.0 million for the year, compared to a loss of approximately HK$61.1 million in 2023[21]. - The basic loss per share amounted to approximately HK$1.35 cents, an increase from approximately HK$0.52 cents in 2023[21]. - For the year ended 31 December 2024, the Group's revenue and gross profit amounted to approximately HK$897.5 million and HK$516.2 million, representing an increase of approximately 10.9% and 9.5% compared to the previous year[44]. - The Group's net loss for the year ended 31 December 2024 was approximately HK$99.0 million, an increase from a net loss of approximately HK$61.1 million in 2023, with basic loss per share at approximately HK$1.35 cents[44]. Dividend Policy - The Board has decided not to recommend any final dividend for the year ended December 31, 2024, consistent with the previous year[18]. - The Company aims to provide stable and sustainable returns to shareholders through its dividend policy, which was adopted in December 2018[19]. - The Company will consider various factors, including operational performance and future prospects, when proposing dividends[19]. - The Group's dividend policy aims for stable and sustainable returns to shareholders, but no final dividend was recommended for the year ended 31 December 2024[22][24]. Business Segments - The pharmaceutical business remains a key pillar for the Group, with plans for sales expansion and enhancement of core competitiveness through research and development[32]. - The fitness business in Singapore is set to introduce a new revenue line of Pilates Reformers in 2025, capitalizing on growing consumer interest[37]. - The Group's fitness business has recovered significantly from the impact of the COVID-19 pandemic, offsetting the adverse effects of decreased royalty fee income[45]. - For the year ended December 31, 2024, the revenue and gross profit of the Group's pharmaceutical business were approximately HK$682.1 million and HK$501.1 million, representing year-on-year increases of approximately 12.3% and 7.3% respectively[48]. - The profit from the pharmaceutical business segment decreased to approximately HK$7.0 million for the year ended December 31, 2024, down from approximately HK$69.6 million in 2023, primarily due to a one-off gain of approximately HK$110.5 million from the disposal of 66% equity interest in Shaanxi Life Care in 2023[49]. - The Group's fitness business revenue was approximately HK$215.4 million for the year ended December 31, 2024, an increase from approximately HK$202.0 million in 2023, with a loss of approximately HK$71.8 million, improved from a loss of approximately HK$81.5 million in 2023[68]. Operational Strategies - The Company is focused on enhancing its market position and exploring new opportunities for growth[17]. - The Group will continue to focus on cost control to mitigate the negative impacts on profitability from product price fluctuations[32]. - The introduction of effective marketing strategies has driven revenue and gross profit growth in the pharmaceutical business segment[45]. - The Group plans to explore new product launches and market entries in alignment with health consumption trends[31]. - The Group will opportunistically commence investment activities to identify a second growth curve[31]. Financial Health and Management - As of 31 December 2024, the Group maintained bank balances and cash reserves of approximately HK$80.6 million, an increase from HK$77.7 million as of 31 December 2023[72]. - The Group had outstanding borrowings repayable within one year of approximately HK$88.1 million, compared to HK$39.5 million in the previous year[73]. - The gearing ratio as of 31 December 2024 was 5.5%, up from 3.0% in 2023, indicating an increase in financial leverage[75]. - The Group's bank borrowings increased to approximately HK$85.5 million in 2024 from HK$28.8 million in 2023[80]. - The Group's staff costs were approximately HK$145.0 million as of 31 December 2024, down from HK$165.0 million in the previous year, reflecting a reduction in employee expenses[86]. Environmental, Social, and Governance (ESG) Initiatives - The report outlines the company's commitment to environmental, social, and governance (ESG) performance, focusing on sustainable operations and stakeholder interests[101]. - The governance structure includes a Board responsible for overseeing ESG policies and an Executive Committee for implementing related measures[109]. - The company has established a robust ESG management framework to ensure effective implementation of policies and risk management[110]. - The report adheres to four principles: materiality, quantitative, balance, and consistency, ensuring comprehensive and comparable ESG disclosures[102]. - The company emphasizes the importance of regular reviews and assessments of ESG performance and objectives by the management[116]. - The Group is developing and implementing an ESG management framework, including strategies and objectives, to enhance sustainable development[117]. - The Executive Committee is responsible for formulating policies and allocating budgets for ESG activities, aligning with the Group's overall business strategy[124]. - The Group has identified key stakeholders and established various communication channels to engage with them regarding ESG issues[128]. - A materiality assessment has been conducted to identify and prioritize key ESG issues relevant to the Pharmaceutical and Fitness businesses[138]. - The Group aims to comply with all applicable environmental requirements and continuously improve its environmental management practices[124]. Waste Management and Emissions - The company has implemented a solar energy generation project in its Beijing plant, covering over 30,000 square feet, fulfilling daily energy consumption needs and selling surplus energy to nearby plants[155]. - The company has replaced gas-fired boilers with electric steam generators to reduce exhaust gas emissions[160]. - The company has installed electrostatic fume purifiers and low-nitrogen burners to monitor and reduce exhaust gas emissions[156]. - The company conducts regular monitoring of exhaust gas emissions to ensure compliance with government regulations and standards[153]. - The company has engaged a qualified inspection company for self-monitoring of pollutant emissions to maintain stable emission levels[160]. - The company is committed to reducing greenhouse gas emissions and has initiated various energy-saving actions[156]. - The company has upgraded its wastewater treatment system to a three-tier deep treatment device to further reduce emissions of harmful gases[159]. - The company emphasizes diversity and inclusion, respecting the labor rights and human rights of all employees[151]. - The company has centralized the handling of hazardous wastes in accordance with relevant laws and regulations, ensuring detoxification treatments by qualified vendors before disposal[166]. - The Group aims to reduce the generation of hazardous and non-hazardous waste and has established waste reduction targets[192]. Resource Optimization - The Group aims to optimize resource usage by implementing the 3R Principle (Reduce, Reuse, Recycle) and improving water recycling utilization rates[199]. - The Group has focused on reducing water consumption in production and enhancing the maintenance and recharge of water sources[200]. - The Group has strengthened the management of raw materials to minimize pollutant generation and sought alternatives for difficult-to-process materials[200]. - The Group has improved operational management for wastewater treatment, significantly reducing technical difficulties and pollution[200]. - The Group's initiatives in resource optimization include energy conservation and water conservation across all business operations[199].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致之任 何損失承擔任何責任。 截至二零二四年十二月三十一日止年度之 經審核業績公告 華控康泰集團有限公司（「本公司」）董事（「董事」）會（「董事會」）宣佈本公司及其附屬公司 （統稱「本集團」）截至二零二四年十二月三十一日止年度之經審核綜合業績如下： 綜合損益及其他全面收益表 截至二零二四年十二月三十一日止年度 | | | 二零二四年 | 二零二三年 | | --- | --- | --- | --- | | | 附註 | 千港元 | 千港元 | | 收入 | 3 | 897,521 | 809,107 | | 銷售及服務成本 | | (381,364) | (337,815) | | 毛利 | | 516,157 | 471,292 | | 其他收入 | 4 | 34,362 | 24,469 | | 其他收益及虧損 | | (26,532) | 111,162 | | 預期信貸虧損模式項下之減值虧損，扣除撥回金額 | | (49, ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of $150 million for the first half of 2024, representing a 25% growth compared to the same period last year[29]. - The company reported a net income of $30 million, reflecting a 50% increase year-over-year[29]. - Revenue for the six months ended June 30, 2024, increased to HK$458,517,000, up 6.5% from HK$430,705,000 in the same period of 2023[33]. - Gross profit for the same period rose to HK$277,146,000, representing a 12.0% increase compared to HK$247,278,000 in 2023[33]. - The Group reported total revenue for the six months ended June 30, 2024, of HK$380,685,000, compared to HK$365,721,000 for the same period in 2023, reflecting an overall increase of approximately 4.4%[43]. - The Group's net loss for the six months ended 30 June 2024 was approximately HK$4.5 million, a turnaround from a net profit of approximately HK$21.4 million in 2023[116]. - Revenue and gross profit for the pharmaceutical business were approximately HK$345.4 million and HK$264.4 million, representing increases of approximately 3.8% and 6.8% compared to the same period in 2023[116]. User Engagement and Market Expansion - User data showed a 30% increase in active users, reaching 1.2 million by the end of June 2024[29]. - The company is planning to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2025[29]. - The fitness business generated revenue of HK$35,295,000 from personal training classes and HK$59,715,000 from membership packages, totaling HK$95,010,000 in fitness-related income for the period[43]. - The fitness business in Singapore is expected to maintain a promising outlook in the second half of 2024, with ongoing strategic initiatives aimed at solidifying business positioning[135]. Investment and Development - Investment in new product development increased by 15%, with a focus on innovative healthcare solutions[29]. - The company emphasized its commitment to sustainability, with plans to reduce carbon emissions by 25% by 2026[29]. - The company has made investments in intangible assets amounting to HK$1,925 during the first half of 2024, reflecting ongoing investment in growth[38]. - The Group aims to strengthen internal management and promote new product development while exploring emerging markets[120]. Financial Position and Cash Flow - Cash flow from operations was strong, totaling $20 million, which supports ongoing investments and operational stability[29]. - The company reported a net current assets position of HK$190,224,000, compared to HK$204,157,000 previously[36]. - The total comprehensive income for the period ended June 30, 2024, was HK$6,753, compared to a loss of HK$1,215 in the same period of 2023, reflecting a positive turnaround[39]. - Cash and cash equivalents at the end of the period were HK$68,663, down from HK$150,606 at the end of June 2023, indicating a decrease in liquidity[39]. - The Group's outstanding borrowings repayable within one year amounted to approximately HK$43.3 million, up from HK$39.5 million as of December 31, 2023[124]. Impairment and Losses - Loss for the period attributable to owners of the company was HK$4,532,000, a significant decline from a profit of HK$21,378,000 in the previous year[34]. - The total impairment losses recognized under the expected credit loss model for the six months ended June 30, 2024, amounted to HK$25,466,000, compared to HK$36,599,000 in the same period of 2023[57]. - An impairment loss on intangible assets related to the franchise agreement in Taiwan was recognized at approximately HK$13,559,000, with no impairment loss reported in the same period of 2023[54][56]. Corporate Governance and Management Changes - The company has maintained compliance with the Corporate Governance Code throughout the period, with a noted deviation regarding the roles of Chairman and CEO[146]. - The company is focusing on enhancing its corporate governance through new appointments in key positions[149]. - The changes in directors are aimed at strengthening the management team and improving operational efficiency[149]. - The Board of Directors has decided not to declare an interim dividend for the six months ended June 30, 2024, to retain funds for future business opportunities[136]. Legal Proceedings and Contingent Liabilities - The Group has contingent liabilities related to legal proceedings from 2019 and 2021, with no material progress made in either case[98]. - The 2019 Legal Proceedings involve claims against the Group regarding a profit guarantee shortfall for the financial years 2017 and 2018, with no trial date set as of the report date[99]. - The management believes the possibility of significant economic outflow related to both legal proceedings is remote[102]. Shareholder Information - China Health Management Investment Limited holds 3,172,778,000 shares, representing 56.77% of the total shareholding[140]. - The total number of shares held by substantial shareholders indicates a strong control over the company[140]. - The maximum number of shares that can be awarded under the Share Award Scheme is capped at 495,000,000 shares, with a limit of 49,500,000 shares for any selected employee[136].

Financial Performance - Revenue for the six months ended June 30, 2024, was HKD 458,517,000, an increase of 6.3% compared to HKD 430,705,000 for the same period in 2023[1] - Gross profit for the same period was HKD 277,146,000, with a gross margin of approximately 60.5%[1] - The net loss for the period was HKD 4,532,000, a significant decrease from a profit of HKD 21,378,000 in the prior year[1] - Other comprehensive income for the period was HKD 3,317,000, compared to a loss of HKD 20,419,000 in the previous year[2] - Basic earnings per share for the period was HKD 0.09, down from HKD 0.70 in the same period last year[2] - The company reported a net loss of HKD 3,672,000 for the six months ended June 30, 2024, compared to a profit of HKD 42,123,000 in the same period last year[16] - The net loss for the group was approximately HKD 4.5 million for the six months ended June 30, 2024, compared to a net profit of approximately HKD 21.4 million in the same period of 2023[26] Assets and Liabilities - Non-current assets totaled HKD 1,097,020,000 as of June 30, 2024, a decrease from HKD 1,139,578,000 at the end of 2023[3] - Current assets amounted to HKD 594,867,000, showing a slight increase from HKD 587,757,000 at the end of 2023[4] - Total liabilities decreased to HKD 226,513,000 from HKD 281,789,000 in the previous period[5] - The company reported a net asset value of HKD 1,060,731,000 as of June 30, 2024, compared to HKD 1,061,946,000 at the end of 2023[5] - The company’s cash and cash equivalents were HKD 68,663,000, down from HKD 77,659,000 at the end of 2023[4] - The total borrowings as of June 30, 2024, were approximately HKD 43.3 million, compared to HKD 39.5 million due within one year at the end of 2023[32] - The asset-liability ratio improved to 2.6% as of June 30, 2024, from 3.0% at the end of 2023[33] Revenue Breakdown - The pharmaceutical business generated revenue of HKD 345,390,000, up from HKD 332,721,000 in the previous year, indicating a growth of about 3.0%[13] - The fitness business reported revenue of HKD 113,127,000, compared to HKD 97,984,000 in the prior year, marking an increase of approximately 15.5%[13] - The pharmaceutical segment's revenue and gross profit were approximately HKD 345.4 million and HKD 264.4 million, reflecting increases of about 3.8% and 6.8% year-on-year[27] - The fitness segment's revenue increased to approximately HKD 113.1 million from HKD 98.0 million in the previous year, while the segment recorded a loss of approximately HKD 38.5 million, an improvement from a loss of HKD 52.1 million in 2023[31] Expenses and Costs - Research and development expenses totaled HKD 4,079,000, significantly reduced from HKD 13,638,000 in the previous year, a decrease of approximately 70.0%[16] - The total depreciation and amortization expenses amounted to HKD 49,685,000, down from HKD 57,780,000 in the previous year, a reduction of about 14.3%[16] - The total tax expense for the six months ended June 30, 2024, was HKD 12,921,000, compared to HKD 27,756,000 in the previous year, indicating a decrease of approximately 53.4%[15] - The group’s employee costs were approximately HKD 75,099,000, down from HKD 81,232,000 for the same period last year[37] Dividends and Shareholder Returns - No interim dividend was recommended for the six months ended June 30, 2024, consistent with the previous year[19] - Basic earnings per share for the six months ended June 30, 2024, were HKD 4,745, compared to HKD 39,138 for the same period in 2023, representing a significant decline[17] - The weighted average number of ordinary shares used for calculating basic earnings per share remained constant at 5,578,713,777 for both periods[17] Legal and Contingent Liabilities - The company is actively defending against legal claims related to a profit guarantee arrangement from a previous acquisition, with low likelihood of significant economic outflow[22][24] - The group has not reported any significant contingent liabilities as of June 30, 2024[24] Operational Insights - The group’s business primarily includes the manufacturing and sale of prescription drugs in China and operating fitness centers, along with franchise operations for royalty income[25] - The group anticipates a bright outlook for its fitness business in Singapore for the second half of 2024, despite rapid changes in the industry[39] - The group is focusing on enhancing product competitiveness through differentiated strategies and exploring new business models to adapt to market changes[38] - The group emphasizes a proactive approach to maintain its competitive edge in the fitness industry and plans to introduce new services and membership plans[39] Workforce and Employment - The group maintained a workforce of 717 employees as of June 30, 2024, slightly down from 720 employees as of December 31, 2023[37] Audit and Compliance - The audit committee reviewed the group's accounting principles and internal controls for the six months ending June 30, 2024[43] - No significant post-reporting date events have occurred since June 30, 2024[44]

Financial Performance - The Group's revenue for the year ended December 31, 2023, was approximately HK$809.1 million, a decrease of approximately 9.5% compared to HK$894.1 million in 2022[13]. - The Group reported a loss of approximately HK$61.1 million for the year, compared to a loss of approximately HK$52.8 million in 2022[13]. - Basic loss per share amounted to approximately HK$0.52 cent, an improvement from HK$0.74 cent in the previous year[17]. - The Board has resolved not to recommend any final dividend for the year ended December 31, 2023[18]. - For the year ended December 31, 2023, the Group's revenue and gross profit were approximately HK$809.1 million and HK$471.3 million, representing a decrease of approximately 9.5% and 6.9% compared to the previous year[39]. - The Group's net loss for the year was approximately HK$61.1 million, a decrease of approximately HK$48.6 million compared to a net loss of approximately HK$109.7 million in 2022[42]. Business Segments - The pharmaceutical business will face increased price competition due to changes in market demand and supply, but the Group aims for moderate growth through new product development and online marketing strategies in 2024[26][27]. - The Group plans to enhance its product mix and consolidate market share to create new earning growth opportunities in the pharmaceutical sector[26]. - The fitness business is expected to achieve sustainable year-on-year growth in new member sales and personal training revenue through innovative marketing strategies and personalized services[31][32]. - The Group's fitness business in Singapore has significantly improved as it recovers from the COVID-19 pandemic, partially offsetting the negative impacts from the pharmaceutical segment[44]. - The Group aims to enrich its product offerings and leverage emerging trends in the fitness industry to capitalize on growth opportunities in 2024[31]. - For the year ended December 31, 2023, the revenue and gross profit of the pharmaceutical business were approximately HK$607.1 million and HK$467.2 million, representing a year-on-year decrease of approximately 16.0% and 10.5% respectively[50]. One-time Gains and Losses - A one-time gain of approximately HK$110.5 million from the disposal of its entire equity interest in Shaanxi Life Care contributed to the improvement in the Group's performance despite unfavorable conditions[42]. - The significant increase in profit for the pharmaceutical business was mainly due to a one-off gain of approximately HK$110.5 million from the disposal of 66% equity interest in Shaanxi Life Care on May 9, 2023[52]. Challenges and Strategies - The decline in pharmaceutical revenue was attributed to adverse impacts from medical insurance policy adjustments and a weak macroeconomic environment affecting customer demand[51]. - The company is actively seeking new customers and orders in response to the challenges faced by Chongqing Kangle due to reduced export demand[60]. - Tongfang Pharmaceutical is facing pressures from new competitive products and is actively seeking countermeasures[58]. - The company’s fitness business was negatively impacted by increased salaries and commissions, reduced government subsidies related to COVID-19, and increased expected credit losses on receivables[63]. Cash Flow and Borrowings - As of 31 December 2023, the Group maintained bank balances and cash reserves of approximately HK$77.7 million, down from approximately HK$122.6 million in 2022[73]. - The Group's outstanding borrowings repayable within one year as of 31 December 2023 were approximately HK$39.5 million, significantly reduced from approximately HK$158.8 million in 2022[74]. - The gearing ratio (total borrowings over total assets) improved to 3.0% in 2023 from 12.4% in 2022[76]. - The Group's bank borrowings were approximately HK$28.824 million as of 31 December 2023, a decrease from approximately HK$206.555 million in 2022[82]. ESG and Corporate Governance - The Group has established a robust ESG governance structure consisting of three levels: the Board, the Executive Committee and management, and the working group and functional departments[108][109]. - The Board is responsible for overseeing the effective implementation of the Group's ESG policies and regularly reviewing the progress of relevant performance and objectives[115][116]. - The Executive Committee and management are tasked with developing and implementing relevant policies and measures in accordance with the ESG strategies set by the Board[116][119]. - The Group emphasizes the importance of stakeholder engagement, incorporating ESG elements into daily operations and assessing their long-term impact[125][126]. - The Group has appointed internal departments and external advisors to review operations and identify relevant ESG issues[126][127]. Environmental Management - The company is committed to operating sustainably while balancing stakeholder interests and positively impacting society[100]. - The Group aims to comply with all applicable environmental requirements and continuously improve its environmental management practices[119][122]. - The Group aims to reduce emissions, water consumption, and resource usage to minimize environmental impact[144]. - The establishment of an energy management system is expected to lower production costs and enhance economic efficiency[143]. - The Group emphasizes strict compliance with environmental protection laws and actively manages exhaust emissions, including formaldehyde and dust[143]. Waste Management - The company has centralized the handling of hazardous wastes and ensured detoxification treatments by qualified vendors before disposal[163]. - The company has implemented waste classification and signed agreements with local waste disposal companies to ensure proper handling of solid waste[162]. - The company aims to reduce hazardous and non-hazardous waste generation through material recovery and negotiation with suppliers[163]. - The Group has implemented waste sorting across all operations, enhancing hazardous waste management to reduce environmental risks[187]. Energy Consumption and Emissions - The company has implemented a Solar Energy Generation Project and various energy conservation measures to reduce emissions[184]. - The company has phased out high-pollution production lines and adopted natural gas as a fuel source to lower emissions[184]. - The clean energy generated from solar power as of 2023 was approximately 1,910,000 kWh, a decrease from approximately 2,490,000 kWh in 2022[194]. - The pharmaceutical business achieved energy savings of up to 40% through the implementation of frequency-controlled refrigeration units[195].

智通财经APP讯，华控康泰(01312)发布公告，黄俞先生(黄先生)因其他工作承担已由公司执行董事调任为非执行董事，自2024年4月19日起生效。彼将同时不再担任集团行政总裁以及董事会执行委员会及董事会股份交易委员会各自的成员。 于2024年4月16日，公司收到深圳市华融泰资产管理有限公司(深圳市华融泰)的函件(提议通知)，要求根据组织章程细则尽快召开及举行公司特别股东大会，以供考虑及酌情通过决议案，以委任王飞飞先生、乔琳娜女士、郭姿秀女士及刘剑焜先生为执行董事;及委任邓丽华博士、何昊洺博士及姚小民先生为独立非执行董事，于有关普通决议案获通过后即时生效(如获通过)。 ...

Financial Performance - For the year ended December 31, 2023, the total revenue was HKD 809,107,000, a decrease of 9.5% from HKD 894,062,000 in 2022[3] - Gross profit for the year was HKD 471,292,000, down 7% from HKD 506,221,000 in the previous year[3] - The company reported a loss from continuing operations of HKD 61,115,000, compared to a loss of HKD 109,744,000 in 2022, indicating an improvement of 44.2%[3] - The total comprehensive loss for the year was HKD 77,636,000, a reduction from HKD 110,907,000 in 2022[4] - Basic loss per share from continuing operations was HKD 0.52, improved from HKD 1.52 in the previous year[6] - The company reported a pre-tax loss of HKD 43,919,000 for 2023, compared to a loss of HKD 117,736,000 in 2022, indicating an improvement in financial performance[25] - The net loss for the fiscal year was approximately HKD 61.1 million, a decrease of about HKD 48.6 million from a net loss of HKD 109.7 million in the previous year[41] Revenue Breakdown - Revenue from the pharmaceutical business was HKD 607,131,000 in 2023, down 16.0% from HKD 722,903,000 in 2022[25] - Revenue from the fitness business increased to HKD 201,976,000 in 2023, up 17.0% from HKD 171,159,000 in 2022[25] - The pharmaceutical segment reported revenue and gross profit of approximately HKD 607.1 million and HKD 467.2 million for the year ending December 31, 2023, representing a year-on-year decline of about 16.0% and 10.5% respectively[44] - Chongqing Kangle's revenue and gross profit decreased by approximately 38.0% and 69.7%, amounting to RMB 72.7 million and RMB 9.0 million respectively, due to reduced customer demand amid a weak macroeconomic environment[48] - The fitness segment's revenue increased to approximately HKD 202.0 million for the year ending December 31, 2023, compared to HKD 171.2 million in 2022, despite a loss of approximately HKD 81.5 million[51] - Shaanxi Chenji's revenue and gross profit fell by approximately 65.4% and 63.6%, amounting to RMB 21.6 million and RMB 9.7 million respectively, prior to its sale[50] Assets and Liabilities - Non-current assets decreased to HKD 1,139,578,000 from HKD 1,430,941,000, reflecting a decline of 20.4%[8] - Current assets decreased to HKD 587,757,000 from HKD 689,502,000, a decline of 14.8%[8] - The company's total equity attributable to shareholders decreased to HKD 1,057,289,000 from HKD 1,101,107,000, a decrease of 4%[9] - The asset-liability ratio improved to 3.0% as of December 31, 2023, down from 12.4% in the previous year, with total borrowings decreasing from HKD 261.9 million to HKD 52.3 million[55] - As of December 31, 2023, the group's bank borrowings amounted to approximately HKD 28,824,000, a decrease from HKD 206,555,000 in 2022[59] Cash Flow and Financing - The company reported a significant reduction in financing costs to HKD 15,250,000 from HKD 23,278,000, a decrease of 34.4%[3] - The cash and cash equivalents decreased to HKD 77,659,000 from HKD 122,595,000, a decline of 36.6%[8] - The company held cash reserves of approximately HKD 77.7 million as of December 31, 2023, down from HKD 122.6 million in the previous year[54] Employee and Operational Costs - The total employee costs for the year were HKD 178.3 million, an increase from HKD 163.6 million in the previous year[32] - The fitness business faced challenges from increased salaries and commissions, reduced government subsidies, and increased expected credit losses on receivables[51] Government Grants and Subsidies - Government grants and subsidies totaled HKD 24,469,000 in 2023, down from HKD 37,928,000 in 2022[28] - The company received government subsidies amounting to approximately HKD 1.335 million, down from HKD 1.568 million in the previous year[30] Corporate Governance and Shareholder Information - The company did not recommend any final dividend for the fiscal year ending December 31, 2023, consistent with the previous year[35] - The board has decided not to recommend any final dividend for the year ended December 31, 2023[65] - The group has complied with all applicable corporate governance codes during the year ended December 31, 2023[67] - The group did not purchase, sell, or redeem any of its listed securities during the year ended December 31, 2023[71] Strategic Initiatives and Future Outlook - The company has restructured its internal reporting framework, leading to changes in the composition of reportable segments[21] - The company is actively seeking new customers and markets to improve performance in the Chongqing Kangle segment for 2024[48] - The pharmaceutical business is expected to face intensified price competition in 2024, prompting the group to enhance product development and marketing strategies[62] - The fitness business aims for sustainable year-on-year growth through innovative marketing and personalized services, capitalizing on emerging trends[63] - The group has implemented strategies to address macro market changes, including online marketing and a new selection plan[62] One-time Gains - The company recorded a one-time gain of approximately HKD 110.5 million from the sale of its entire equity interest in Shaanxi Chenji, contributing to the improvement in performance despite declines in revenue and gross profit[41] - The sale of 66% equity in Shaanxi Chenji Pharmaceutical Group on May 9, 2023, resulted in a one-time gain of approximately HKD 110.5 million, which offset some of the declines in revenue and gross profit[44] Employee Count - The group had 720 employees as of December 31, 2023, down from 922 in 2022[61] Meeting and Share Transfer Information - The group will hold its annual general meeting on June 7, 2024, with a suspension of share transfer registration from June 3 to June 7, 2024[66]

Financial Performance - Revenue for the six months ended June 30, 2023, was HK$430,705,000, a decrease of 4.5% compared to HK$451,085,000 in the same period of 2022[13]. - Gross profit for the same period was HK$247,278,000, down from HK$267,475,000, reflecting a decline of 7.5%[13]. - Profit before taxation improved to HK$42,123,000, compared to a loss of HK$70,492,000 in the prior year[13]. - Profit for the period from continuing operations was HK$21,378,000, a significant recovery from a loss of HK$67,470,000 in the previous year[13]. - Total comprehensive income for the period was HK$959, compared to a comprehensive loss of HK$58,250,000 in the same period last year[13]. - For the six months ended June 30, 2023, the profit attributable to owners of the Company from continuing operations was HK$39,138,000, compared to a loss of HK$51,154,000 in the same period of 2022, representing a significant turnaround[15]. - The total comprehensive income attributable to owners of the Company for the period was HK$19,383,000, compared to a loss of HK$49,010,000 in the prior year, indicating improved financial performance[15]. - Basic earnings per share from continuing operations increased to HK$0.70, up from a loss of HK$0.92 per share in the previous year[15]. - For the six months ended June 30, 2023, the company reported a profit of HK$39,138,000, compared to a loss of HK$31,178,000 for the same period in 2022, marking a significant turnaround[21]. - The total profit (loss) attributable to owners of the Company for the six months ended 30 June 2023 was HK$39,138,000, while for the same period in 2022 it was a loss of HK$31,178,000[91]. - The net profit for the same period was approximately HK$21.4 million, a turnaround from a net loss of approximately HK$67.5 million in 2022, resulting in a basic earnings per share of approximately HK$0.007[193]. - The Group's net profit for the six months ended 30 June 2023 was approximately HK$21.4 million, a turnaround of approximately HK$88.9 million compared to a net loss of approximately HK$67.5 million in 2022[195]. Revenue Breakdown - Pharmaceutical business revenue was HK$332,721,000, down 10.2% from HK$370,379,000 in the previous year[49]. - Fitness business revenue increased to HK$97,984,000, up 21.4% from HK$80,706,000 in the prior year[49]. - Revenue from personal training classes in the fitness segment was HK$33,000,000, an increase of 12.0% from HK$29,258,000[49]. - Membership package revenue in the fitness segment rose to HK$44,486,000, up 36.3% from HK$32,624,000[49]. - Revenue from royalty fees related to fitness and health activities was HK$20,498,000, an increase of 9.0% from HK$18,824,000[49]. - Revenue from Mainland China was HK$325,828,000, a decrease of 10.8% from HK$365,167,000 in the previous year[49]. - The decline in revenue and gross profit was primarily due to adverse impacts from medical insurance policy adjustments in Mainland China and a weak macroeconomic environment affecting customer demand[190][193]. - The fitness business segment in Singapore showed significant improvement as it gradually recovered from the COVID-19 pandemic, partially offsetting the negative impacts from the pharmaceutical segment[190]. Expenses and Costs - Distribution and selling expenses decreased to HK$216,049,000, down 7.8% from HK$234,213,000[13]. - Administrative expenses were reduced to HK$55,229,000, a decrease of 11.4% from HK$62,386,000[13]. - The company reported a cost of inventories recognized as expenses of HK$81,170,000 for the period, down from HK$86,469,000 in the previous year, reflecting a decrease of approximately 6.1%[79]. - The total amortization and depreciation expenses for the period were HK$57,780,000, down from HK$65,037,000 in 2022, which is a decrease of approximately 11.1%[79]. - Cost control measures adopted by the Group were effective in offsetting some of the revenue declines[198]. Assets and Liabilities - Non-current assets decreased to HK$1,143,419,000 as of June 30, 2023, down from HK$1,430,941,000 at the end of 2022, reflecting a reduction in property, plant, and equipment[17]. - Current assets slightly decreased to HK$683,954,000 from HK$689,502,000, with cash and cash equivalents increasing to HK$150,606,000 from HK$122,595,000[19]. - Total liabilities decreased to HK$378,525,000 from HK$504,707,000, primarily due to a reduction in bank borrowings due within one year[19]. - The equity attributable to owners of the Company increased to HK$1,120,490,000 as of June 30, 2023, compared to HK$1,101,107,000 at the end of 2022, indicating a strengthening balance sheet[19]. - The Company reported a net current assets position of HK$305,429,000, up from HK$184,795,000, highlighting improved liquidity[19]. - Total consolidated assets decreased to HK$1,827,373,000 as of June 30, 2023, from HK$2,120,443,000 as of December 31, 2022, reflecting a decline of approximately 13.8%[58]. - The total consolidated liabilities decreased to HK$686,832,000 as of June 30, 2023, from HK$964,162,000 as of December 31, 2022, representing a decline of approximately 28.9%[58]. - The Group's bank borrowings decreased to HK$49,880,000 as of June 30, 2023, down from HK$206,555,000 on December 31, 2022, representing a reduction of approximately 76.1%[131]. Gains and Losses - The significant increase in profit to approximately HK$108.5 million in 2023 was mainly due to a one-off gain of approximately HK$110.5 million from the sale of a 66% stake in Shaanxi Zhi Guang Chen Ji Pharmaceutical Co., Ltd.[200]. - The Group recorded a one-off gain on the disposal of subsidiaries of approximately HK$110.5 million, contributing to the overall profit[198]. - The gain on disposal of subsidiaries for the six months ended June 30, 2023, was HK$110,491,000, compared to HK$2,998,000 in the same period of 2022, reflecting a significant increase[67]. - The company reported a net loss on the disposal and write-off of property, plant, and equipment of HK$366,000 for the six months ended June 30, 2023, compared to a loss of HK$1,589,000 in the same period of 2022, indicating an improvement of about 77%[67]. Strategic Focus and Future Outlook - The Company has not disclosed any new product developments or market expansion strategies during this reporting period[20]. - Future outlook and performance guidance were not explicitly detailed in the provided documents[20]. - The Group's management continues to focus on expanding its fitness and health consultation services alongside its pharmaceutical operations[188]. - The Group's strategic focus remains on enhancing operational efficiency and market presence in both the pharmaceutical and fitness sectors[188].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 截至二零二三年六月三十日止六個月之 未經審核中期業績 華控康泰集團有限公司（「本公司」）董事（「董事」）會（「董事會」）宣佈本公司及其附屬公司 （「本集團」）截至二零二三年六月三十日止六個月之未經審核簡明綜合中期業績連同二零 二二年同期之比較數字如下。本集團截至二零二三年六月三十日止六個月之中期財務業 績乃未經審核，但已由本公司審核委員會（「審核委員會」）及本公司核數師香港立信德豪 會計師事務所有限公司作出審閱。 簡明綜合損益及其他全面收益表 截至二零二三年六月三十日止六個月 截至六月三十日止六個月 二零二三年 二零二二年 附註 千港元 千港元 （未經審核） （未經審核） 持續經營業務 收入 5 430,705 451,085 銷售及服務成本 (183,427) (183,610) ...

Financial Performance - The Group's revenue for the year ended December 31, 2022, was approximately HK$894.1 million, an increase of approximately 11.3% compared to HK$803.3 million in 2021[14][18]. - The Group reported a loss of approximately HK$52.8 million for the year, compared to a loss of approximately HK$4.6 million in 2021[14][18]. - Basic loss per share amounted to approximately HK$0.74 cent, compared to approximately HK$0.27 cent in the previous year[18]. - The net loss for the year ended December 31, 2022, was approximately HK$109.7 million, an increase of approximately HK$53.4 million compared to the net loss of HK$56.3 million in 2021[44]. - Basic loss per share for 2022 was approximately HK$1.52 cents, compared to HK$0.86 cents in 2021[44]. - The increase in net loss was attributed to higher distribution and selling expenses due to market expansion in the pharmaceutical segment[46]. - The fitness business of the Group generated revenue of approximately HK$171.2 million in 2022, an increase of approximately 6.1% from HK$161.3 million in 2021[74]. - The net loss for the Group's fitness business widened to approximately HK$46.0 million in 2022, compared to HK$26.4 million in 2021[74]. Dividend Policy - The Board has resolved not to recommend any final dividend for the year ended December 31, 2022[19]. - The Company adopted a dividend policy in December 2018, aiming for stable and sustainable returns to shareholders[20]. Business Segments - The Group focuses on human health and aims to create value for all stakeholders through quality services[24]. - The pharmaceutical business segment did not experience supply chain disruptions in 2022, which positively impacted sales, unlike in 2021 when a major supplier failed to deliver on time[41]. - The fitness business segment showed gradual improvement as it overcame the impacts of the COVID-19 pandemic[44]. - Government grants and subsidies related to the COVID-19 pandemic decreased compared to the previous year, impacting the fitness business segment[46]. - The Group plans to focus on the development of its existing advantageous chemical generic medicine and active pharmaceutical ingredients industries[29]. - The Group aims to extend its business reach to emerging sub-sectors to provide better long-term returns to shareholders[29]. Employee and Operational Metrics - The Group had 922 employees as of December 31, 2022, a decrease of 29.4% from 1,305 employees in 2021[99]. - As of December 31, 2022, the Group maintained bank balances and cash reserves of approximately HK$122.6 million, down from approximately HK$174.2 million in 2021[84]. - The Group's outstanding borrowings repayable within one year were approximately HK$158.8 million as of December 31, 2022, compared to approximately HK$226.7 million in 2021[85]. - The gearing ratio of the Group as of December 31, 2022, was 12.4%, up from 9.5% in 2021[87]. Environmental, Social, and Governance (ESG) Initiatives - The Group's environmental, social, and governance report outlines its commitment to sustainable operations and stakeholder interests[108]. - The Group is committed to operating sustainably, balancing stakeholder interests while positively impacting society[112]. - The ESG Report is prepared based on principles of materiality, quantitative data, balance, and consistency[113]. - The Board oversees the effective implementation of ESG policies, including risk management and performance review[120]. - The Executive Committee and management are responsible for formulating policies and allocating budgets for ESG activities[134]. - The Group aims to comply with all applicable environmental requirements and continuously improve its environmental management practices[134]. - A robust ESG governance structure has been established, consisting of the Board, Executive Committee, management, and working groups[121]. - The Group integrates data from functional departments and subsidiaries to assess ESG performance[135]. - Regular assessments of ESG-related progress and performance are conducted, with reports submitted to the Board[128]. - The Group's strategy focuses on promoting sustainable economies and enhancing value for business partners and shareholders[134]. Waste and Emissions Management - The company aims to reduce gas emissions by regularly conducting exhaust gas monitoring to meet government emission standards, including the Emission Standard of Air Pollutants for Catering Industry and others[162]. - The company has reduced indirect CO2 emissions from electricity consumption to approximately 2,110 tons in 2022, down from 4,034 tons in 2021, with a per capita CO2 density of 3.25 tons[169]. - The company has eliminated heavily-polluted production lines and replaced facilities to reduce emissions, including installing electrostatic fume purifiers and low-nitrogen burners[166]. - The company has upgraded its wastewater treatment system to a three-stage process to further reduce emissions of harmful gases like formaldehyde[168]. - The company has implemented energy-saving actions and purchased new exhaust treatment equipment to enhance emission reduction efforts[168]. - The company has focused on monitoring and controlling the concentration of exhaust gas emissions to ensure compliance with pollutant discharge permits[166]. - The Group has implemented waste sorting and hazardous waste management, signing disposal agreements to enhance treatment efficiency and reduce environmental risks[189]. - The Fitness Business reported no significant emissions of hazardous and non-hazardous wastes in 2022[189]. Renewable Energy Initiatives - A solar energy power generation project has been implemented in the Beijing plant, covering over 30,000 square feet, fulfilling daily energy consumption needs, and selling surplus energy to nearby plants[165]. - The company generated approximately 2,490,000 kWh of clean energy from solar power in 2022, a decrease from approximately 3,910,000 kWh in 2021[198]. - The total electricity consumption for the year 2022 was 6.99 million kWh, down from 13.36 million kWh in 2021, with a per capita electricity consumption density of 0.0108 million kWh[200]. - The company has implemented energy-saving measures, including phasing out high-energy-consuming refrigeration equipment, which has improved production efficiency[200]. Challenges and Market Conditions - Shaanxi Unisplendour faced challenges due to rising raw material prices and the lingering effects of the COVID-19 pandemic[65]. - Chongqing Kangle experienced negative impacts from rising raw material prices and extreme weather conditions in 2022[69]. - The overall operation of Tongfang Pharmaceutical returned to normal levels in 2022, aided by the absence of major product supplier delivery failures[58].